Skip to main content
Clinical Trials/NCT05922202
NCT05922202
Recruiting
Not Applicable

Influence of Frailty on Cardiovascular Events and Mortality in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Multicentre Observational Study.

Azienda Ospedaliero-Universitaria di Modena1 site in 1 country300 target enrollmentFebruary 23, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Role of Frailty in COPD
Sponsor
Azienda Ospedaliero-Universitaria di Modena
Enrollment
300
Locations
1
Primary Endpoint
Number of cardiovascular events in COPD patients living with frailty vs non-frail COPD. patients.
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

Observational study on the influence of frailty on cardiovascular risk in COPD.

Detailed Description

The study will investigate the influence that frailty can have on cardiovascular risk in patients with COPD. The project will assess the association between frailty and all-cause mortality, and the relationship between frailty and cardiovascular mortality, by comparing COPD patients living with frailty vs non-frail COPD patients. The study participants will be outpatients with diagnosis of COPD according to the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines (www.goldcopd.org). Frailty will be measured using the Clinical Frailty Scale (grades 1-9). Patients who are terminally ill (CFS = 9) will be excluded. Cognitive function will be explored using the Montreal Cognitive Assessment (MoCA) test. The follow up will be at 12 and 24 months.

Registry
clinicaltrials.gov
Start Date
February 23, 2024
End Date
June 30, 2026
Last Updated
9 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Alessia Verduri

Dr Alessia Verduri

Azienda Ospedaliero-Universitaria di Modena

Eligibility Criteria

Inclusion Criteria

  • Patients with age ≥18 years, with diagnosis of COPD of at least 1 year, in stable condition, without acute exacerbation in the last 30 days and/or all-cause hospitalisation in the last 3 months
  • Smoking history of ≥ 10 pack/years
  • Diagnosis of COPD according to GOLD guidelines (www.goldcopd.org)
  • Individuals able to provide their written informed consent.

Exclusion Criteria

  • Concurrent diagnosis of interstitial lung disease
  • Presence of restrictive pattern on spirometry
  • No history of smoking habit
  • Individuals not able to provide their written informed consent.

Outcomes

Primary Outcomes

Number of cardiovascular events in COPD patients living with frailty vs non-frail COPD. patients.

Time Frame: 12 and 24 months

Number of cardiovascular events (including hospital admissions for cardiovascular events) at 12 and 24 months in COPD patients living with frailty vs non-frail COPD patients.

Secondary Outcomes

  • Prevalence of frailty in COPD.(Baseline, at 12 and 24 months)
  • All-cause long-term mortality in COPD patients living with frailty vs non-frail COPD patients.(12 and 24 months)
  • Cardiovascular mortality in COPD patients living with frailty vs non-frail COPD patients.(12 and 24 months)
  • Deaths due to COPD in COPD patients living with frailty vs non-frail COPD patients.(12 and 24 months)

Study Sites (1)

Loading locations...

Similar Trials